CRA published a report for Pharmaceutical Care Management Association on the potential effects on proposed changes to the definition of Medicare Part D prices. To read the report, click the link below.
Rare disease PMA trends in France: Price achieved vs. disease prevalence
In this installment, we examine the relationship between launch prices in France and disease prevalence as reported in the Haute Autorité de Santé assessments.